BATUL LUKMANJI: Open Payments
NPI 1568006674 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,329 in 168 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $1,545 · 2025 $3,329
Food & beverage: $3,314Education: $15
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 34 | $643 |
| ABBVIE INC. | 14 | $311 |
| Janssen Pharmaceuticals, Inc | 9 | $292 |
| Alkermes, Inc. | 15 | $271 |
| Otsuka America Pharmaceutical, Inc. | 12 | $232 |
| Teva Pharmaceuticals USA, Inc. | 13 | $211 |
| Supernus Pharmaceuticals, Inc. | 13 | $179 |
| E.R. Squibb & Sons, L.L.C. | 9 | $159 |
| Neurocrine BioSciences, Inc. | 5 | $154 |
| Bausch Health US, LLC | 8 | $151 |
Products named: REXULTI, VRAYLAR, SPRAVATO, ARISTADA, Qelbree, COBENFY, INGREZZA, APLENZIN.
Industry payments across TX — which companies pay providers there.
